HLB Life Science Co

HLB Life Science Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of HLB Life Science Co (067630.KQ) as of Nov 3, 2026 is -22.38. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -16.91 — a change of 32.33% (lower).

EV/OCF

-22.38

YoY

32.33%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of HLB Life Science Co is 2025 -22.38 . EV/OCF (Enterprise Value to Operating Cash Flow) of HLB Life Science Co was 2024 -16.91 . It decreases by 32.33% lower compared to the previous year.

The HLB Life Science Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-32.30 KRW
Jan 1, 2019
-23.81 KRW
Jan 1, 2020
155.28 KRW
Jan 1, 2021
-22.96 KRW
Jan 1, 2022
-16.07 KRW
Jan 1, 2023
-50.94 KRW
Jan 1, 2024
-16.91 KRW
Jan 1, 2025
-22.38 KRW
The HLB Life Science Co EV/OCF history
YEAREV/OCFYoY
-22.38+32.33%
-16.91-66.80%
-50.94+216.98%
-16.07-30.02%
-22.96-114.79%
155.28-752.10%
-23.81-26.28%
-32.30-97.78%
-1,456.40+606.61%
-206.11+92.67%
-106.98-337.67%
45.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB Life Science Co Stock analysis

What does HLB Life Science Co do? HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB Life Science Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of HLB Life Science Co is -22.38 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of HLB Life Science Co changed from -16.91 to -22.38, representing a 32.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) HLB Life Science Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s HLB Life Science Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — HLB Life Science Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — HLB Life Science Co